Epigenetics of Severe Systemic Inflammation
严重全身炎症的表观遗传学
基本信息
- 批准号:7847303
- 负责人:
- 金额:$ 37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-06-05 至 2009-11-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAnti-Inflammatory AgentsAnti-inflammatoryBindingBiochemicalBloodCell modelCharacteristicsChromatinClinicalCoupledCytosineDNADNA BindingDNA Modification MethylasesDNA SequenceDataDiseaseEpigenetic ProcessEuchromatinGene ExpressionGene SilencingGenesGeneticGenetic TranscriptionHeterochromatinHistone CodeHistone H3HistonesHumanHypermethylationImmunoblottingImmunosuppressionInflammationInflammatoryInterleukin-1LeukocytesLysineMass Spectrum AnalysisMessenger RNAMethylationMethyltransferaseNucleosomesOutcomePatientsPhosphotransferasesPlasmidsProcessProtein DephosphorylationProtein-Serine-Threonine KinasesProteinsPublic HealthRPS6KA5 geneReportingRepressionSepsisSerineSmall Interfering RNATNF geneTestingTissuesTransfectionTransferaseTranslational ResearchTraumaabstractingadapter proteinantimicrobial peptidebasechromatin immunoprecipitationcytokinegene repressiongenetic regulatory proteinheterochromatin-specific nonhistone chromosomal protein HP-1histone methyltransferasehuman diseaseimprovednovel therapeutic interventionpromoterpublic health relevanceresponse
项目摘要
Abstract
Epigenetic gene reprogramming is an emerging concept relevant to human diseases. This proposal's
objective is to investigate epigenetics of severe systemic inflammation (SSI). SSI blood and tissue leukocytes
show gene-specific reprogramming with repressed transcription of acute proinflammatory genes like TNF and
IL-1 and activated transcription of other gene sets. SSI gene reprogramming reversal correlates with clinical
improvement. We reported TNF transcription repression and a nucleosome shift to lysine 9 H3 di-methylation
(H3K9me2), H3 serine 10 dephosphorylation(H3S10), and repressor heterochromatin protein 1 (HP-1)
promoter binding in an SSI cell model. We further implicate the histone H3 lysine methyltransferase G9a
coupled to HP-1 and CpG methylation by cytosine methyltransferase DNMT 3a/b during TNF silencing.
Together, these results support that epigenetic mechanisms participate in repressing acute inflammatory
genes and sustaining often lethal immunosuppression observed in SSI patients. We hypothesize that SSI
generates a shift from a euchromatin (responsive) heterochromatin (silenced) at the proximal promoter of
acute proinflammatory genes. Aim 1 will test in whether the euchromatin to heterochromatin shift requires
specific H3 serine kinases, lysine methyltransferases and demethylases, and adapters or linkers, and the
potential for reversibility. Aim 2 will test whether acute proinflammatory gene promoter CpG methylation is
coupled through specific regulatory proteins to the nucleosome shifts. Aim 3 will test whether the epigenetic
shift from euchromatin to heterochromatin occurs in circulating human SSI leukocytes. Experimental
approaches for the basic (Aims 1 and 2) and translational aims (Aim 3) will include genetic (transfection of
siRNA or expression plasmids) and biochemical (chromatin immunoprecipitation, DNA sequencing, DNAase
footprinting, immunoblots, and mRNA quantitation) analyses.
*
摘要
表观遗传基因重编程是与人类疾病相关的一个新兴概念。这个提议
目的探讨严重全身性炎症(SSI)的表观遗传学。SSI血液和组织白细胞
显示基因特异性重编程,抑制急性促炎基因如TNF的转录,
IL-1和其他基因组的激活转录。SSI基因重编程逆转与临床
改进.我们报道了肿瘤坏死因子转录抑制和核小体转移到赖氨酸9 H3二甲基化
(H3 K9 me 2)、H3丝氨酸10去磷酸化(H3 S10)和阻遏异染色质蛋白1(HP-1)
SSI细胞模型中的启动子结合。我们进一步暗示组蛋白H3赖氨酸甲基转移酶G9 a
在TNF沉默期间,通过胞嘧啶甲基转移酶DNMT 3a/B偶联HP-1和CpG甲基化。
总之,这些结果支持表观遗传机制参与抑制急性炎症反应。
在SSI患者中观察到的基因和持续的通常致命的免疫抑制。我们假设SSI
产生从常染色质(响应性)异染色质(沉默)在近端启动子的转变,
急性促炎基因Aim 1将测试常染色质向异染色质的转移是否需要
特异性H3丝氨酸激酶、赖氨酸甲基转移酶和脱甲基酶,以及衔接子或接头,以及
可逆性的潜力。目的2将检测急性促炎基因启动子CpG甲基化是否与急性炎症相关。
通过特定的调节蛋白与核小体移位偶联。目标3将测试表观遗传是否
从常染色质到异染色质的转变发生在循环的人SSI白细胞中。实验
用于基本(目标1和2)和转化目标(目标3)的方法将包括遗传(转染
siRNA或表达质粒)和生物化学(染色质免疫沉淀、DNA测序、DNA酶
足迹法、免疫印迹和mRNA定量)分析。
*
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Charles Emory McCall其他文献
Charles Emory McCall的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Charles Emory McCall', 18)}}的其他基金
Redox control over metabolism and mitochondrial bioenergetics directs the course of acute inflammation and sepsis.
氧化还原对代谢和线粒体生物能学的控制指导急性炎症和脓毒症的进程。
- 批准号:
9916767 - 财政年份:2018
- 资助金额:
$ 37万 - 项目类别:
Redox control over metabolism and mitochondrial bioenergetics directs the course of acute inflammation and sepsis.
氧化还原对代谢和线粒体生物能学的控制指导急性炎症和脓毒症的进程。
- 批准号:
10398109 - 财政年份:2018
- 资助金额:
$ 37万 - 项目类别:
Redox control over metabolism and mitochondrial bioenergetics directs the course of acute inflammation and sepsis
氧化还原对代谢和线粒体生物能学的控制指导急性炎症和脓毒症的进程
- 批准号:
10001885 - 财政年份:2018
- 资助金额:
$ 37万 - 项目类别:
Mitochondrial Biogenesis is Regulated by RelB During Inflammation
炎症过程中线粒体生物合成受 RelB 调节
- 批准号:
8696501 - 财政年份:2014
- 资助金额:
$ 37万 - 项目类别:
Mitochondrial Biogenesis is Regulated by RelB During Inflammation
炎症过程中线粒体生物合成受 RelB 调节
- 批准号:
9265879 - 财政年份:2014
- 资助金额:
$ 37万 - 项目类别:
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 37万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 37万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 37万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 37万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 37万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 37万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 37万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 37万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 37万 - 项目类别: